A Study of Deucravacitinib to Treat LPP and FFA

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
Mayo Clinic
Study ID
NCT06091956
Phase
PHASE2
Status
Completed

Conditions

  • Lichen Planopilaris

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this clinical research study is to learn more about the use of Deucravacitinib in the treatment of Lichen Planopilaris.

Key Dates

Start date
Nov 7, 2023
Status verified
Jun 2025
Primary completion
May 21, 2024
Completion
Dec 24, 2024

Study Design

Enrollment
12 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Deucravacitinib Treatment for Lichen Planopilaris
    Subjects diagnosed with Lichen Planopilaris (LP) will receive Deucravacitinib for 24 weeks.

Primary Outcome Measure

Complete and Partial Response to Deucravacitinib Measured by Lichen Planopilaris Activity Index (LPPAI) Score [ Time Frame: 24 weeks ]

Locations (2)

FacilityCityStateZIPSite coordinators
Mayo Clinic ArizonaScottsdaleArizona85259-
Mayo Clinic FloridaJacksonvilleFlorida32224-

Related coverage on Hipa.ai

Find similar trials in Scottsdale, AZ

By research site
Mayo Clinic Arizona· Scottsdale, AZMayo Clinic Florida· Jacksonville, FL

Related Studies